EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Formulation and stability design spaces for a new yellow fever vaccine

Didier Clénet, Noémie Mansois, Yawen Guo, Bruna Araujo Dos Ramos, Landry Bertaux, Manuel Vangelisti

European Journal of Pharmaceutics and Biopharmaceutics · 2026

DOI: 10.1016/j.ejpb.2026.115177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026. Verfasst von Didier Clénet und 5 weiteren Autor:innen. Beteiligte Einrichtung: Global Bioprocess Development, Vaccine CMC Development & Supply, Sanofi, Marcy l'Etoile, France. Electronic address: didier.clenet@sanofi.com. Hauptthemen laut MEDLINE: Yellow Fever Vaccine, Yellow Fever. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi Pasteur SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Yellow fever (YF) is a life-threatening disease that is entirely preventable through vaccination. The objective of this study was to formulate a freeze-dried presentation of a live-attenuated, Vero cell-based yellow fever vaccine (vYF) with improved manufacturability and enhanced shelf-life. Considering four critical quality attributes (i.e., glass transition temperatures and infectious titers at two time points), a comprehensive formulation screening was performed to identify an optimal combination of excipients, capable of protecting the virus during lyophilization while ensuring long-term stability of the vYF infectious titer. Overall, L-proline, urea, and poloxamer 407 demonstrated a stabilizing effect, and the application of an advanced kinetic model enabled prediction of a 60-month shelf-life at 5 °C for the formulated vaccine. Machine learning models were used to build both formulation and stability design spaces that defined global stabilizing regions within the explored concentration ranges of each excipient. This study demonstrates that the combination of systematic excipient screening and advanced analytics enables the selection of robust formulations with long-term stability within an accelerated development timeframe. The developed vaccine formulation has the potential for large-scale industrial production and can address substantial market demand in the coming years, representing a significant advancement in vYF technology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Yellow Fever VaccineYellow FeverExcipientsAnimalsDrug StabilityVero CellsChlorocebus aethiopsYellow fever virusChemistry, PharmaceuticalFreeze DryingVaccines, AttenuatedDrug CompoundingMachine Learning

Stichwörter der Autor:innen

Formulation developmentMachine learningQbDStability modelingYellow fever vaccine

Substanzen

Yellow Fever VaccineExcipientsVaccines, Attenuated

Autor:innen und Institutionen

  • Global Bioprocess Development, Vaccine CMC Development & Supply, Sanofi, Marcy l'Etoile, France. Electronic address: didier.clenet@sanofi.com.
  • Center of Excellence, Capgemini Engineering, Lyon, France.
  • Global Bioprocess Development, Vaccine CMC Development & Supply, Sanofi, Marcy l'Etoile, France.
  • Global CMC Leadership, Sanofi, Marcy l'Etoile, France.
  • R&D Global Projects Strategy and Execution, Sanofi, Marcy l'Etoile, France.

Förderung

  • Sanofi Pasteur SA

Zitieren

APA

Clénet, D., Mansois, N., Guo, Y., Dos Ramos, B. A., Bertaux, L., & Vangelisti, M. (2026). Formulation and stability design spaces for a new yellow fever vaccine. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2026.115177

Vancouver

Clénet D, Mansois N, Guo Y, Dos Ramos BA, Bertaux L, Vangelisti M. Formulation and stability design spaces for a new yellow fever vaccine. European Journal of Pharmaceutics and Biopharmaceutics. 2026. doi:10.1016/j.ejpb.2026.115177

BibTeX
@article{Clnet2026,
  author = {Clénet, Didier and Mansois, Noémie and Guo, Yawen and Dos Ramos, Bruna Araujo and Bertaux, Landry and Vangelisti, Manuel},
  title = {Formulation and stability design spaces for a new yellow fever vaccine},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2026},
  doi = {10.1016/j.ejpb.2026.115177}
}
Kostenlos starten →